Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment

Eur Urol. 2022 Dec;82(6):599-601. doi: 10.1016/j.eururo.2022.08.031. Epub 2022 Sep 13.

Authors

Hannah E Dzimitrowicz¹, Andrew J Armstrong²

Affiliations

¹ Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
² Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA. Electronic address: andrew.armstrong@duke.edu.

PMID: 36114081
DOI: 10.1016/j.eururo.2022.08.031

No abstract available

Publication types

Editorial
Comment

MeSH terms

Androgen Antagonists
Hormones
Humans
Male
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology

Substances

Androgen Antagonists
Hormones